The challenges of lupus anticoagulants

Expert Review of Hematology

Volumn 9, Issue 4, 2016, Pages 389-400

  Chighizola, Cecilia Beatrice ^a,b   Raschi, Elena ^b   Banzato, Alessandra ^c   Borghi, Maria Orietta ^a,b   Pengo, Vittorio ^c   Meroni, Pier Luigi ^a,b,d  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Anti 2 glycoprotein Iantibodies; Antiphospholipid syndrome; Antiprothrombin antibodies; Detection; Lupus anticoagulant; Pregnancy complications; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; LUPUS ANTICOAGULANT; BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY;

ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; DABOIA RUSSELLII; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; LIVER CELL; NONHUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBIN TIME; THROMBOSIS; TROPHOBLAST; BLOOD; COMPLICATION; FEMALE; IMMUNOLOGY; PARTIAL THROMBOPLASTIN TIME; PATHOLOGY; PREGNANCY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 84958536919     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2016.1140034     Document Type: Review

References (72)

1. Pengo V, Bison E, Denas G, et al. The paradox of the lupus anticoagulant: history and perspectives. Semin Thromb Hemost. 2014; 40: 860-865.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295-306.
3. Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014; 36: 35263,36.
4. Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res. 2013; 65: 1869-1873.
5. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8: 237-242.
6. Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009; 68: 397-399.
7. Chighizola CB, Andreoli L, De Jesus GR, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Lupus. 2015; 24: 980-984.
8. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 2003; 101: 1827-1832.
9. Reynaud Q, Lega J-C, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-Analysis. Autoimmun Rev. 2014; 13: 595-608.
10. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: A metaanalysis. J Rheumatol. 2006; 33: 2214-2221.
11. Abou-Nassar K, Carrier M, Ramsay T, et al. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-Analysis. Thromb Res. 2011; 128: 77-85.
12. De Laat B, Derksen RHWM, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005; 105: 1540-1545.
13. Bevers EM, Galli M, Barbui T, et al. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991; 66: 629-632.
14. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood. 1993; 81: 2618-2625.
15. Pengo V, Biasiolo A, Rampazzo P, et al. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost. 1999; 81: 256-258.
16. Pengo V, Balestrieri G, Tincani A, et al. Utilization of dilute Russells viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost. 1997; 77: 123-126.
17. Simmelink MJ, Horbach DA, Derksen RH, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol. 2001; 113: 621-629.
18. Dienava-Verdoold I, Boon-Spijker MG, De Groot PG, et al. Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. J Thromb Haemost. 2011; 9: 738-747.
19. Lai CJ, Rauch J, Cho CS, et al. Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus. J Autoimmun. 1998; 11: 39-51.
20. Arnout J, Vanrusselt M, Wittevrongel C, et al. Monoclonal antibodies against beta-2-glycoprotein I: use as reference material for lupus anticoagulant tests. Thromb Haemost. 1998; 79: 955-958.
21. Sakai Y, Atsumi T, Ieko M, et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum. 2009; 60: 2457-2467.
22. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005; 3: 1231-1238.
23. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: Anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep. 2014; 16: 402-409.
24. Takeya H, Mori T, Gabazza EC, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest. 1997; 99: 2260-2268.
25. De Laat HB, Derksen RHWM, Urbanus RT, et al. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004; 104: 3598-3602.
26. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: Antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015; 13: 782-787.
27. Pengo V, Ruffatti A, Tonello M, et al. Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res. 2015; 136: 161-163.
28. Andreoli L, Chighizola CB, Nalli C, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-Glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 As a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol. 2015; 67: 2196-2204.
29. Agostinis C, Durigutto P, Sblattero D, et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014; 123: 3478-3487.
30. Pregnolato F, Chighizola CB. Phospholipid autoantibodies (non-Anticardiolipin)-Antiprothrombin antibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. Oxford: Elsevier; 2014. p. 741-749.
31. Bevers EM, Zwaal RFA, Willems GM. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Clin Immunol. 2004; 112: 150-160.
32. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988; 72: 512-519.
33. Simmelink MJA, De Groot PG, Derksen RHWM. A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. J Thromb Haemost. 2003; 1: 735-739.
34. Pengo V, Denas G, Bison E, et al. Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res. 2010; 126: 150-153.
35. Pregnolato F, Chighizola CB, Encabo S, et al. Anti-phosphatidylserine/prothrombin antibodies: An additional diagnostic marker for APS? Immunol Res. 2013; 56: 432-438.
36. Arvieux J, Darnige L, Caron C, et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995; 74: 1120-1125.
37. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009; 7: 1737-1740.
38. Keeling D, Mackie I, Moore GW, et al. British committee for standards in haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012; 157: 47-58.
39. Ledford-Kraemer MR, Moore GW, Bottenus R, et al. Laboratory testing for the lupus anticoagulant; approved guideline. CLSI Document H60. Wayne (PA): Clinical and Laboratory Standards Institute; 2014.
40. Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost. 1989; 62: 892-896.
41. Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol. 2014; 36: 364-373.
42. Chantarangkul V, Tripodi A, Arbini A, et al. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res. 1992; 67: 355-365.
43. Moore GW, Savidge GF. Heterogeneity of Russells viper venom affects the sensitivity of the dilute Russells viper venom time to lupus anticoagulants. Blood Coagul Fibrinolysis. 2004; 15: 279-282.
44. Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun. 2000; 15: 179-183.
45. Kumano O, Ieko M, Naito S, et al. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent. J Thromb Haemost. 2012; 10: 2338-2343.
46. Moore GW. Clinical utility of the less commonly employed assays for lupus anticoagulation detection: The evidence. J Coagul Disord. 2010; 2: 69-79.
47. Mackie IJ, Lawrie AS, Greenfield RS, et al. A new lupus anticoagulant test based on dilute prothrombin time. Thromb Res. 2004; 114: 673-674.
48. Simmelink MJA, Derksen RHWM, Arnout J, et al. A simple method to discriminate between beta2-glycoprotein I-And prothrombin-dependent lupus anticoagulants. J Thromb Haemost. 2003; 1: 740-747.
49. Pengo V, Biasiolo A, Pegoraro C, et al. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost. 2004; 2: 702-707.
50. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014; 13: 917-930.
51. Oosting JD, Derksen RH, Entjes HT, et al. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost. 1992; 67: 499-502.
52. Pennings MTT, De Groot PG, Meijers JCM, et al. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma? Thromb Haemost. 2014; 112: 736-742.
53. Chandler JB, Torres R, Rinder HM, et al. Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives. Br J Haematol. 2014; 167: 704-707.
54. Devreese KMJ, De Laat B. Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J Thromb Haemost. 2015; 13: 1475-1478.
55. Isert M, Miesbach W, Stoever G, et al. Screening for lupus anticoagulants in patients treated with vitamin K antagonists. Int J Lab Hem. 2015; 37: 758-765. doi: 10.1111/ijlh.12409.
56. Kershaw G, Suresh S, Orellana D, et al. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost. 2012; 38: 375-384.
57. Arachchillage DR, Mackie IJ, Efthymiou M, et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2015; 13: 1264-1273.
58. Van Os GMA, De Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011; 9: 1657-1659.
59. De Groot PG, Lutters B, Derksen RHWM, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005; 3: 1993-1997.
60. Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res. 2015; 135: 46-49.
61. Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007; 27: e309e310.
62. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007; 5: 925-930.
63. Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013; 11: 1527-1531.
64. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet Neurol. 2009; 8: 998-1005.
65. Gebhart J, Posch F, Koder S, et al. Increased mortality in patients with the lupus anticoagulant: The Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood. 2015; 125: 3477-3483.
66. Sailer T, Vormittag R, Pabinger I, et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol. 2005; 32: 462-468.
67. Just SA, Nybo M, Laustrup H, et al. Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia. Lupus. 2015; pii: 09612033156004040.
68. Schouwers SME, Delanghe JR, Devreese KMJ. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res. 2010; 125: 102-104.
69. Reber G, Meijer P. In ECAT veritas?. Lupus. 2012; 21: 722-724.
70. Cervera R, Asherson RA. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. Immunobiology. 2005; 210: 735-741.
71. Lechner K, Simonitsch I, Haselböck J, et al. Acquired immune-mediated thrombophilia in lymphoproliferative disorders. Leuk Lymphoma. 2011; 52: 1836-1843.
72. Chighizola CB, Ubiali T, Meroni PL. Treatment of thrombotic antiphospholipid syndrome: The rationale of current management-An insight into future approaches. J Immunol Res. 2015; 2015: 951424. DOI: 10.1155/2015/951424.